肥胖症治疗神经调控系统市场规模、份额和成长分析：按产品类型、应用、最终用户和地区划分－2026-2033年产业预测

2024年全球用于肥胖治疗的神经调控系统市场价值为25亿美元，预计将从2025年的27.1亿美元成长到2033年的52.1亿美元。预测期（2026-2033年）的复合年增长率预计为8.5%。

全球用于治疗肥胖症的神经调控系统市场涵盖了植入式和非侵入式设备，这些设备旨在影响控制食慾、饱腹感和新陈代谢的神经通路。随着肥胖率的上升，医疗保健系统面临越来越大的压力，凸显了传统治疗方法无法满足的患者需求。在设备技术创新的推动下，该领域的发展已从胃电刺激设备转向先进的迷走神经疗法。推动该市场发展的关键因素是临床疗效与监管核准和保险覆盖范围之间关联性证据的积累，这正在推动更广泛的应用。此外，人工智慧 (AI) 透过实现自适应控制系统、个人化治疗和远端监测，提高了治疗的有效性和可近性，最终为改善患者预后和拓展神经调控疗法的临床路径铺平了道路。

全球肥胖症治疗神经调控系统市场驱动因素

肥胖症盛行率的不断上升推动了对有效长期解决方案的需求，迫使医疗专业人员探索标准疗法以外的替代治疗方法。不断扩大的患者群体推动了对神经调控技术的投资，因为临床医生相信这些技术能够提供持续的体重管理，尤其是在传统行为疗法和药物疗法中效果有限的情况下。随着人们对肥胖相关严重併发症的认识不断提高，专科医疗机构对基于设备的治疗方法的应用正在不断推进，培训和转诊流程也不断加强。因此，製造商正致力于开发和推广能够满足临床医生和患者需求的创新解决方案，从而进一步推动市场成长并拓展产品平臺。

全球肥胖症治疗神经调节系统市场面临的限制因素。

全球用于肥胖症治疗的神经调控系统市场面临许多限制因素，阻碍其成长与普及。除了设备和手术相关的高昂初始成本外，不同医疗保险计划中不明确或有限的报销选项也对医院和支付方造成负面影响。这种情况降低了医疗机构将患者转介至神经调控治疗的意愿。此外，支付方通常要求提供长期临床效益和成本效益的全面证据才能批准保险覆盖，这使得试验过程复杂化，并为医疗机构和患者都带来了经济风险。因此，小规模的诊所可能不愿投资于专业化和培训，导致儘管临床实践热情高涨，但其地理扩张缓慢，市场整合程度有限。

全球肥胖症治疗神经调控系统市场趋势

全球用于肥胖治疗的神经调控系统市场正经历着向个人化神经刺激疗法的重大转变。这种疗法专注于根据每位患者的生理功能和肥胖表型客製化刺激参数和设备设定。这种个人化方法，得益于影像和感测技术的进步，能够实现自适应治疗通讯协定，从而增强对食慾和代谢途径的调节作用。随着患者疗效和生活品质日益受到重视，设备製造商、医疗服务提供者和数位健康平台之间的合作也不断加强。这有助于实现个人化治疗流程，并促进患者持续参与肥胖管理。

目录

介绍

• 调查目的
• 市场定义和范围

调查方法

• 研究过程
• 二级资料和一级资料的方法
• 市场规模估算方法

执行摘要

• 全球市场展望
• 市场主要亮点
• 细分市场概览
• 竞争环境概述

市场动态及展望

• 总体经济指标
• 促进者和机会
• 抑制因素和挑战
• 供给面趋势
• 需求面趋势
• 波特的分析和影响

市场考察

• 关键成功因素
• 影响市场的因素
• 主要投资机会
• 生态系测绘
• 2025年市场吸引力指数
• PESTEL 分析
• 监理情势
• 价值链分析
• 监管分析

全球用于肥胖症治疗的神经调控系统市场规模：按产品类型和复合年增长率划分（2026-2033 年）

• 植入式神经控制系统
• 非植入式/外在神经调节系统

全球用于肥胖症治疗的神经调控系统市场规模：按应用和复合年增长率划分（2026-2033 年）

• 减重管理
• 代谢性疾病治疗
• 行为健康干预

全球用于肥胖症治疗的神经调控系统市场规模：按最终用户和复合年增长率划分（2026-2033 年）

• 医院
• 门诊手术中心
• 研究机构
• 居家医疗环境

用于肥胖症治疗的神经调控系统全球市场规模及复合年增长率（2026-2033 年）

• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业的市场定位（2025 年）
• 主要市场公司采取的策略
• 近期市场趋势
• 企业市占率分析（2025 年）
• 主要企业公司简介
  • 公司详情
  • 产品系列分析
  • 按细分市场进行企业市占率分析
  • 2023-2025年营收年比比较

主要企业简介

• EnteroMedics Inc.
• Intrapace Inc.
• Medtronic plc
• Boston Scientific Corporation
• ReShape Lifesciences Inc.
• Gelesis Inc.
• Dune Medical Devices
• Obesity Surgical Solutions
• Atheromed LLC
• Stimwave LLC
• Nevro Corp.
• Synchrony Health Services
• Ethicon Endo-Surgery
• Apollo Endosurgery Inc.
• Aspire Bariatrics Inc.
• ZeaVision
• VWave LLC
• Intuitive Surgical Inc.
• Echosens
• Minimally Invasive Surgical Technologies

结论与建议

Global Obesity Treating Neuromodulation System Market size was valued at USD 2.5 Billion in 2024 and is poised to grow from USD 2.71 Billion in 2025 to USD 5.21 Billion by 2033, growing at a CAGR of 8.5% during the forecast period (2026-2033).

The global market for obesity-treating neuromodulation systems includes both implantable and noninvasive devices designed to influence neural pathways that govern appetite, satiety, and metabolism. As obesity rates rise, healthcare systems face increased pressure, highlighting the unmet needs of patients with conventional treatments. The evolution of this field has transitioned from gastric electrical stimulators to advanced vagal nerve therapies, supported by innovations in device technology. A critical driver in this market is the growing body of evidence linking clinical efficacy to regulatory approvals and reimbursement, which facilitates broader adoption. Additionally, artificial intelligence enhances treatment efficacy and accessibility by enabling adaptive control systems, personalized treatment, and remote monitoring, ultimately paving the way for better patient outcomes and expanding clinical pathways for neuromodulation therapies.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Obesity Treating Neuromodulation System market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Obesity Treating Neuromodulation System Market Segments Analysis

Global obesity treating neuromodulation system market is segmented by product type, application, end-user and region. Based on product type, the market is segmented into Implantable Neuromodulation Systems and Non-implantable / External Neuromodulation Systems. Based on application, the market is segmented into Weight Loss Management, Metabolic Disorders Treatment and Behavioral Health Interventions. Based on end-user, the market is segmented into Hospitals, Ambulatory Surgical Centers, Research Institutes and Home Care Settings. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Obesity Treating Neuromodulation System Market

The increasing prevalence of obesity is driving a higher demand for effective long-term solutions, leading healthcare professionals to explore alternative treatment options beyond standard approaches. This expanding population of patients is fueling investments in neuromodulation technologies, as there is a belief among clinicians in their potential to provide lasting weight management, particularly where traditional behavioral and pharmacological strategies may fall short. The acknowledgment of serious complications associated with obesity is fostering the adoption of device-based therapies in specialized medical facilities, enhancing training and referral practices. Therefore, manufacturers are focusing on developing and marketing innovative solutions to fulfill the needs of both clinicians and patients, further propelling market growth and expanding the product pipeline.

Restraints in the Global Obesity Treating Neuromodulation System Market

The Global Obesity Treating Neuromodulation System market faces several constraints that hinder its growth and adoption. Significant initial costs associated with devices and procedures, coupled with unclear or restricted reimbursement options in various healthcare systems, negatively impact hospitals and payers. This situation diminishes the likelihood of providers referring patients for neuromodulation treatments. Furthermore, payers often demand comprehensive evidence of long-term clinical advantages and cost-effectiveness prior to granting coverage, complicating the trial process and imposing financial risks on both healthcare institutions and patients. Consequently, smaller clinics may be reluctant to invest in specialized technology and training, resulting in slower geographical expansion and limited market integration despite clinical enthusiasm.

Market Trends of the Global Obesity Treating Neuromodulation System Market

The Global Obesity Treating Neuromodulation System market is witnessing a significant shift towards personalized neurostimulation therapies, which focus on customizing stimulation parameters and device configurations based on individual patient physiology and obesity phenotypes. This tailored approach enhances the modulation of appetite and metabolic pathways, bolstered by advancements in imaging and sensing technologies that inform adaptive treatment protocols. With a growing emphasis on demonstrable improvements in patient outcomes and quality of life, there is a rising collaboration among device manufacturers, healthcare providers, and digital health platforms, paving the way for customized treatment journeys and ongoing patient engagement in obesity management.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape
• Value Chain Analysis
• Regulatory Analysis

Global Obesity Treating Neuromodulation System Market Size by Product Type & CAGR (2026-2033)

• Market Overview
• Implantable Neuromodulation Systems
• Non-implantable / External Neuromodulation Systems

Global Obesity Treating Neuromodulation System Market Size by Application & CAGR (2026-2033)

• Market Overview
• Weight Loss Management
• Metabolic Disorders Treatment
• Behavioral Health Interventions

Global Obesity Treating Neuromodulation System Market Size by End-User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Ambulatory Surgical Centers
• Research Institutes
• Home Care Settings

Global Obesity Treating Neuromodulation System Market Size & CAGR (2026-2033)

• North America (Product Type, Application, End-User)
  • US
  • Canada
• Europe (Product Type, Application, End-User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product Type, Application, End-User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product Type, Application, End-User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product Type, Application, End-User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• EnteroMedics Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Intrapace Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medtronic plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boston Scientific Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ReShape Lifesciences Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gelesis Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dune Medical Devices
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Obesity Surgical Solutions
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Atheromed LLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Stimwave LLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nevro Corp.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Synchrony Health Services
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ethicon Endo-Surgery
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Apollo Endosurgery Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aspire Bariatrics Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ZeaVision
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• VWave LLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Intuitive Surgical Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Echosens
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Minimally Invasive Surgical Technologies
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations